{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Peltrini R"],"funding":["Community of Analytical Measurement Science (CAMS UK)","Medical Research Council and Engineering &amp; Physical Sciences Research Council","Medical Research Council and Engineering &amp; Physical Sciences Research Council (Molecular Pathology Node)","Leicester NIHR Biomedical Research Centre","Imperial NIHR Biomedical Research Center","Community of Analytical Measurement Science"],"pagination":["1101-1112"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11544360"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["210(9)"],"pubmed_abstract":["<b>Rationale:</b> Volatile organic compounds (VOCs) in asthmatic breath may be associated with sputum eosinophilia. We developed a volatile biomarker signature to predict sputum eosinophilia in asthma. <b>Methods:</b> VOCs emitted into the space above sputum samples (headspace) from patients with severe asthma (<i>n</i> = 36) were collected onto sorbent tubes and analyzed using thermal desorption gas chromatography-mass spectrometry (GC-MS). Elastic net regression identified stable VOCs associated with sputum eosinophilia ⩾ 3% and generated a volatile biomarker signature. This VOC signature was validated in breath samples from: <i>1</i>) patients with acute asthma according to blood eosinophilia ⩾0.3 × 10<sup>9</sup>cells/L or sputum eosinophilia of ⩾3% in the UK EMBER (East Midlands Breat"],"journal":["American journal of respiratory and critical care medicine"],"pubmed_title":["Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma."],"pmcid":["PMC11544360"],"funding_grant_id":["MR/N005880/1","Respiratory theme"],"pubmed_authors":["Hedlin G","Bakke P","Wilson S","Pennazza G","James A","Heaney L","Yasinska V","Gaillard E","Nehrig J","Mansoor S","Skipp PJ","Konradsen J","Caruso M","Lazic Z","Golbach E","Cornacchini SB","Renwick L","Haitchi HM","Wheelock A","Wheelock C","Brinkman P","Adcock IM","Richardson M","Santonico M","Walker S","Postle T","Coleman C","Reynolds JC","Platt A","Nizankowska E","Chanez P","Sandstrom T","Andersson L","Bourke AM","Ibrahim W","the EMBER EPSRC/MRC Consortium and the U-BIOPRED-IMI Study Group","Kearley J","Djukanovic R","Frey U","Singer F","Kots M","Maitland van der Zee AH","Ibrahim M","Krug N","Staudinger H","Stefanuto PH","Cordell RL","Shaw D","Alving K","Peltrini R","Zounemat-Kermani N","Skrgat S","Ostling J","Baribaud F","Affleck K","Schleich F","Hashimoto S","Thomas P","Quek E","Powell P","Higenbottam T","Sousa A","Zhou H","Zounemat Kermani N","Zhao B","van den Heuvel M","Clokie MRJ","Singapuri A","Soderhall C","Louis R","Brightling C","Armin B","Monks P","Bush A","Howarth P","Olin AC","Bansal A","Chung F","Barer MR","Khokhlovich E","Roberts A","Clarke G","Wagener A","Badi Y","Kolmert J","Aung H","Dahlen SE","Le Quesne J","Bel EHD","De Meulder B","Brandsma J","Free RC","Roberts G","Muton R","Siddiqui S","Horvath​ IK","Fowler S","Penate Gomez D","Palkonen S","Murray C","Musial J","Danen C","Sterk PJ","Abuhelal S","Govoni M","Sun K","Rao N","Raffaele A","Wilde M","Faner R","Shaw JA","Uddin","Corfield J","Tenselius O","Yang F","Compton C","Geiser T","Ezerskyte M","Samani NJ","Hohlfeld J","Rupani H","Salman D","Greening N","Romagosa S","Agusti A","Guo YK","Auffray C","Montuschi P","Suzuki T","Nordlund B","de Sousa D","Dahlen B","Hou R","Hargadon B","Azim A","Sigmund R","Knowles R","Loza MJ","Salas M","Versi A","Needham K","Damera G","Csoma Z","Cordell R","Ng L","Horvath I","DaVeiga S","de Vries R","Poinasamy K","Xavier J","Schofield","Hekking PW","Goodhall AH","Supple D","Vestbo J","Coats T","Pandya HC","Wikstrom Jonsson E","Sparreman Mikus M","Ostridge K","Olsson HK","Louise J F","Mjosberg J","Mumby S","Maier D","Warren L","Spruit M"],"additional_accession":[]},"is_claimable":false,"name":"Discovery and Validation of a Volatile Signature of Eosinophilic Airway Inflammation in Asthma.","description":"<b>Rationale:</b> Volatile organic compounds (VOCs) in asthmatic breath may be associated with sputum eosinophilia. We developed a volatile biomarker signature to predict sputum eosinophilia in asthma. <b>Methods:</b> VOCs emitted into the space above sputum samples (headspace) from patients with severe asthma (<i>n</i> = 36) were collected onto sorbent tubes and analyzed using thermal desorption gas chromatography-mass spectrometry (GC-MS). Elastic net regression identified stable VOCs associated with sputum eosinophilia ⩾ 3% and generated a volatile biomarker signature. This VOC signature was validated in breath samples from: <i>1</i>) patients with acute asthma according to blood eosinophilia ⩾0.3 × 10<sup>9</sup>cells/L or sputum eosinophilia of ⩾3% in the UK EMBER (East Midlands Breat","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-05T07:46:30.41Z","creation":"2026-05-14T03:12:18.393Z"},"accession":"S-EPMC11544360","cross_references":{"pubmed":["38820123"],"doi":["10.1164/rccm.202310-1759OC","10.1164/rccm.202310-1759oc"]}}